CLINICAL TRIALS PROFILE FOR LATUDA
✉ Email this page to a colleague
All Clinical Trials for latuda
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00833976 ↗ | Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia | Completed | GlaxoSmithKline | Phase 4 | 2009-07-01 | This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated. |
| NCT00833976 ↗ | Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia | Completed | Massachusetts General Hospital | Phase 4 | 2009-07-01 | This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated. |
| NCT01143077 ↗ | A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents | Completed | Sunovion | Phase 3 | 2010-06-01 | Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effectiveness, safety, and tolerability of switching clinically stable, but symptomatic outpatients with schizophrenia or schizoaffective disorder from their preswitch antipsychotic medication to lurasidone, over a period of 6 weeks. |
| NCT01284517 ↗ | Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression | Completed | Sunovion | Phase 3 | 2010-11-01 | Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression. This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective among patients with bipolar I depression. |
| NCT01421134 ↗ | Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose | Completed | Sunovion | Phase 3 | 2011-09-01 | Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features. |
| NCT01423240 ↗ | Major Depressive Disorder With Mixed Features | Withdrawn | Sunovion | Phase 3 | 2012-01-01 | Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for latuda
Condition Name
Clinical Trial Locations for latuda
Trials by Country
Clinical Trial Progress for latuda
Clinical Trial Phase
Clinical Trial Sponsors for latuda
Sponsor Name
